Medical Affairs Manager, TTR Cardiomyopathy - Germany

This role is considered [[custWorkplaceType]].

Medical Affairs Manager, TTR Cardiomyopathy  - Germany

Location: Germany - virtual
Department: Medical Affairs

Overview

The Medical Affairs Manager (MAM) is a scientific and clinical expert who strategically drives and supports the medical objectives of Alnylam in the designated therapeutic area(s).

They will provide support to all functions within the country to ensure achievement of local objectives, in close collaboration with International and Global Medical Affairs. They will put the patient at the centre of their work, operating with the highest ethical and scientific standards, and continuously advancing evidence-based medical standards of care.

The Medical Affairs Manager is expected to build strong cross-functional relationships with colleagues in Medical Affairs, Clinical Research, R&D, Patient Advocacy, and Commercial Operations, while maintaining full compliance with all relevant company, industry, legal, and regulatory requirements.

Key Responsibilities

• Support cross-functional launch readiness and critical business operations post-launch activities.
• Develop and continuously maintain the highest scientific and medical expertise within TTR Cardiomyopathy (CM) and be acknowledged internally and externally as an expert in this area, developing peer-to-peer scientific relationships with HCPs and giving medical support to the corresponding cross-functional disease area teams.
• Collaborate with the Medical Affairs Manager for TTR Polyneuropathy to develop and implement a comprehensive Country Medical Affairs Plan and Strategy to support disease awareness, best clinical practice, and the overall corporate objectives.
• Identify key opinion leaders and cultivate a network of experts for TTR CM.
• Initiate and support high-impact medical education activities, including congress symposia, hospital or healthcare professional educational meetings, as well as provide medical and scientific input into the planning and execution of advisory boards.
• Actively engage with International and Global Medical Affairs and other functions, providing medical leadership within TTR CM to ensure effective local implementation of Alnylam’s strategy and appropriate use of local market intelligence and development opportunities.
• Collaborate with patient advocacy groups.
• Manage requests for Alnylam product supply in off-label and compassionate use cases, in accordance with local laws and Alnylam procedures.
• Coordinate the timely and appropriate response to Medical Information inquiries, utilizing global medical information resources and ensuring compliance with local regulatory requirements.
• Support internal stakeholders in the Market Access process, including AMNOG.
• Train internal team members in relevant therapy areas and provide product training.

Qualifications

• MD (Medical Doctor) and/or PhD and/or equivalently academically qualified healthcare professional. A degree in medical or natural science (PhD, MD) is preferred.
• Previous experience in the field of cardiology in the German market strongly preferred.
• Proven basic science and/or clinical background enabling meaningful scientific engagement with healthcare professionals.
• Strong analytical skills as applied to medical, scientific, and technical information, with the ability to simplify scientific complexity.
• Experience in clinical research and investigator-sponsored trials.
• Experience in medical education and KOL engagement programs.
• Effective communication skills for evidence-based scientific exchange.
• Knowledge of drug development, GCP, and local regulations.
• Ability to work collaboratively and cross-functionally.
• Strong management, planning, decision-making, and accountability skills.
• Confidence and professional competence to gain respect and credibility at all levels within and outside the company, with the capability to represent the company externally.
• Fluent in German and English, both written and verbal.
• Willingness to travel 50–60% of the time.

Why Alnylam?

Join a company recognized for its innovation, open culture, and commitment to people. At Alnylam, you’ll work in an environment that values collaboration, purpose, and excellence — and be part of a team bringing groundbreaking RNAi therapies to patients in need.

Apply now to make a difference where science meets purpose.

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.